Medtech Monday: Bullish Bets on Breakthroughs - Examining Cutting-Edge Trials and Investment Opportunities Attention all healthcare and biotech investors! Buckle up for a deep dive into the hottest clinical trials poised to shape the future of medicine in 2024 and beyond. To get a detailed report, contact us at - info@insights10.com, visit - https://bit.ly/3uGcvZW
2. Source: FDA
Molecule Brand Name Manufacturer
Name Phase (Jan 2024)
ATR inhibitor + PDL-1 mAb
PD-1/CTLA-4
bispecific mAb Volrustomig
STING Agonist TAK-500
Ceralasertib + Imfinzi Phase III, expected filing in 2024
Phase III, new to this phase
Phase III
Phase II
BTK inhibitor + R-CHOP Calquence + R-CHOP
3. Phase II
Phase II
Source: FDA
Molecule Brand Name Manufacturer
Name Phase (Jan 2024)
CD27 agonist mAb
BTK inhibitor + BCL-2
inhibitor + anti-CD20 mAb
Calquence + venetoclax +
obinutuzumab
Targeted Next Generation
Interferon
EGFR x CD3 Conditional T-
cell engager
Modakafusp Alfa
TAK-186
Boserolimab
Phase II, in combination with KEYTRUDA
Phase II
4. Phase II
Source: FDA
Molecule Brand Name Manufacturer
Name Phase (Jan 2024)
SUMOylation Inhibitor
Anaplastic Lymphoma
Kinase (ALK) inhibitor Brigatinib
EGFR/HER2 inhibitor mobocertinib
Subasumstat (TAK-981)
Phase II
Phase II